RPG LIFERPG Life Sciences LimitedNSE:RPGLIFETechnicalAnalystSucritRPG Life Sciences Ltd. (CMP ₹2,955.00, NSE: RPGLIFE) The SmartWay Research Desk | 29 September 2026 A Mumbai‑based pharmaceutical company, incorporated in 2007. RPG Life Sciences Ltd. is engaged in formulations, active pharmaceutical ingredients (APIs), and biotechnology products, with a strong presence in cardiology, nephrology, gastroenterology, oncology, and dermatology. The company exports to multiple international markets while maintaining a robust domestic branded formulations business. Promoter Holding (Jun 2026): RPG Enterprises (Goenka Family Group) — ~72.1% stake (no pledges) FY22–FY26 Snapshot Revenue Growth: FY26 revenue ₹842 Cr vs ₹742 Cr in FY25 (+13.5% YoY). → Good Net Profit: FY26 PAT ₹142 Cr vs ₹122 Cr in FY25 (+16.4% YoY). → Good Operating Margin: FY26 EBITDA ₹212 Cr, margin 25.2% vs 24.1% last year (+110 bps). → Good Equity Capital: Stable, face value ₹8. → Good Dividend Policy: Dividend ₹20.00/share declared for FY26. → Good Asset Building: Investments in API manufacturing, quality systems, and product portfolio expansion. → Good Sales: Strong demand from chronic therapy segments and export markets. → Good Expense: R&D and compliance costs remain elevated. → Neutral/Good EPS: FY26 EPS ₹48.25 vs ₹41.60 last year (+16.0%). → Good Institutional Interest & Ownership Trends (Jun 2026) Promoter Holding: ~72.1% (no pledges) FII Holding: ~2.4% DII Holding: ~8.2% Retail & Others: ~17.3% Strategic Moves & Innovations Expansion in high‑margin chronic therapies and specialty formulations. Focus on API backward integration and export growth. Investments in R&D and product registrations in regulated markets. Strengthening domestic branded formulations portfolio. Cash Flow & Balance Sheet Strength Market cap ~₹4,900 Cr. Debt‑to‑equity ratio ~0.05 (very low leverage). Book value per share ₹235.00; P/B ~12.6. EPS (TTM) ₹48.25; P/E ~61.2. Risk Factors High P/E ratio ~61.2, indicating premium valuations. Dependence on regulatory approvals and export market growth. Exposure to pricing pressure in pharmaceutical markets. Competition from Alembic Pharma, IPCA Labs, and Eris Lifesciences. Investor Takeaway RPG Life Sciences has delivered consistent growth in revenue, profitability, and operating margins, supported by its strong branded formulations business and API operations. With backing from the RPG Group, low debt, healthy cash generation, and focus on chronic therapies, the company remains a quality mid‑cap pharmaceutical play. At CMP ₹2,955.00, valuations are premium (P/E ~61.2, P/B ~12.6), reflecting investor confidence in its niche pharma portfolio and long‑term growth prospects.